Subscribe to Smart Business Dealmakers
January 19, 2024
Clarametyx Biosciences Announces $33M Series A
Clarametyx Biosciences Inc., a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, announced the successful...
By Staff Reports
September 1, 2023
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity
Carmell Corporation, a regenerative care company announced the successful closing of the previously announced merger with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company...
By Dan Pender
December 23, 2019
Zafgen, Chondrial Therapeutics to merge
The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics Inc....
By Adam Burroughs
December 17, 2019
Roche, Spark Therapeutics deal approved (finally)
Roche and Spark Therapeutics Inc. have completed their acquisition deal following the receipt of regulatory approval from all government authorities required by the merger agreement....
By Adam Burroughs
December 9, 2019
Aevi Genomic Medicine to be acquired by Cerecor for $16M+
The combined bio-pharmaceutical company will continue to be focused on pediatric orphan diseases and operate under the name Cerecor....
By Adam Burroughs
December 5, 2019
Limelight Bio gets $75M from Apple Tree Partners
Limelight Bio has raised $75 million in new financing funded by Apple Tree Partners, a life sciences innovation fund....
By Adam Burroughs
November 25, 2019
VenatoRx to get $4.1M from Boston’s CARB-X
Malvern’s VenatoRx Pharmaceuticals Inc. is receiving up to $4.1 million in non-dilutive funding from Boston’s CARB-X to develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant Neisseria gonorrhoeae....
By Adam Burroughs
November 12, 2019
MOBILion Systems raises $15.4M Series A
MOBILion Systems Inc. has raised $15.4 million in Series A financing. The round was led by Agilent Technologies, with participation from IP Group Inc., Hostplus, Cultivation Capital, and iSelect Fund....
By Adam Burroughs
November 12, 2019
BioLife Solutions Buys Custom Biogenic Systems
CBS, a privately held company with operations located near Detroit, is a global leader in the design and manufacture of state-of-the-art liquid nitrogen laboratory freezers and cryogenic equipment....
By Mark Scott
October 17, 2019
Mebias Discovery closes $3.5M raise
The investment will be used by Mebias Discovery to expand its pipeline with new gastrointestinal and inflammation programs, applying the company’s novel platform to find drugs with significantly less, or negative, on‑target adverse effects....
By Adam Burroughs
October 16, 2019
Achillion Pharmaceuticals to be bought by Alexion Pharmaceuticals
The initial consideration of approximately $930 million, or $6.30 per share of Achillion common stock, will be funded by Alexion with cash on hand....
By Adam Burroughs
October 16, 2019
Galera Therapeutics launches IPO
Galera Therapeutics, a Malvern-based biopharmaceutical firm, has filed to go public on the Nasdaq stock exchange under the ticker symbol of GRTX. The expected offering amount is $86....
By Adam Burroughs
October 3, 2019
Cabaletta Bio files for IPO
The company plans to use the money to fund manufacturing capabilities and translational research to complement its relationship with the Center for Cellular Immunotherapies at the University of Pennsylvania....
By Adam Burroughs
September 30, 2019
Ocugen completes merger with Histogenics
The combined company’s name will be “Ocugen Inc,” and the company is expected to begin trading on September 30, 2019, on The Nasdaq Capital Market....
By Adam Burroughs
September 27, 2019
ExpressCells completes Series A round with $1.2M total raise
ExpressCells is using the funding to build its commercial and operational infrastructure....
By Adam Burroughs
September 17, 2019
Navrogen raises $3.2M in funding
Navrogen Inc. has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities....
By Adam Burroughs
September 13, 2019
Castle Creek to buy Fibrocell Science
With the resources of CCP Holdings' subsidiary, Castle Creek Pharmaceuticals LLC, Fibrocell's gene therapy platform can be advanced into additional areas of high, unmet need with the potential to develop multiple, promising new therapies....
By Adam Burroughs
September 9, 2019
SequenceBase bought by Clarivate Analytics
SequenceBase is being acquired by Clarivate Analytics in a move expected to deliver an expanded solution to the fast-growing biologics market....
By Adam Burroughs
September 4, 2019
Passage Bio closes $110M Series B round
Passage Bio has closed a $110.0 million Series B financing....
By Adam Burroughs
September 3, 2019
Gyroscope Therapeutics raises $62M Series B round
Gyroscope Therapeutics, headquartered in Ambler, has raised a $62.2 million (£50.4 million) Series B financing round....
By Adam Burroughs
September 3, 2019
Roche extends Spark offer (yes, again) giving more time for regulatory approval
Roche has again extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock of Spark Therapeutics Inc. for $114.50 per share....
By Adam Burroughs
August 8, 2019
Keystone Biologicals bought by BioIVT
Keystone Biologicals Inc., a supplier of disease-state plasma, sera and controls, located in Hatboro, Pennsylvania, has been acquired by BioIVT in a deal expected to expand BioIVT's disease-state portfolio both by volume and product range....
By Adam Burroughs
July 24, 2019
Pennsylvania Biotechnology Center launches Hatch BioFund Management investment arm
The Pennsylvania Biotechnology Center, a life science incubator, launched its Hatch BioFund Management LLC, a $50 million internal investment arm meant to support its early-stage companies....
By Adam Burroughs
July 16, 2019
Convelo Therapeutics agreement with Genentech opens door to acquisition
Convelo Therapeutics Inc., a Cleveland-based biotechnology company, has entered into an exclusive worldwide collaboration with Genentech, a member of the Roche Group. Through the deal, Genentech retains an exclusive option to acquire Convelo....
By Adam Burroughs
July 11, 2019
Orchestra BioMed completes $34M Series B-1 preferred stock financing round
New Hope-based Orchestra BioMed Inc., a biomedical innovation company working in procedure-based medicine, has completed a $34 million Series B-1 preferred stock financing....
By Adam Burroughs
July 8, 2019
Spark, Roche deal put on hold
Spark Therapeutics’ acquisition by Roche has been put on hold as the two companies agreed to extend the deadline for the Swiss drugmaker’s $4.3 billion takeover bid for the U.S. gene therapy specialist, according to Reuters. The report noted that Roche remains committed to a deal....
By Adam Burroughs
July 1, 2019
Century Therapeutics gets $250M in funding
The funding from Bayer, Versant and Fujifilm Cellular Dynamics will allow Century to move multiple programs into clinical development for hematologic and solid malignancies....
By Adam Burroughs
April 12, 2019
NEO bioscience companies landed $294M in 2018
Dealmaking is hot in Northeast Ohio’s biomedical community, with 71 regional companies receiving $294 million in funding in 2018. BioEnterprise’s Aram Nerpouni explains how this dealmaking trend could become the “new normal.”...
By Mark Scott
